Real-world Effectiveness and Use of Efgartigimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE REAL Study Design
Benjamin Knier1, Jana Zschüntzsch2, Zoreh Akhavan Aghdam3, Jamie Aldridge3, Jeffrey Allen4, Filip Eftimov5, Desiree Gneissl3, Saman Haghighi3, Geoffrey Istas3, Chris Pashos3, Rebecca Traub6, Chafic Karam7
1Diak-Klinikum Landkreis Schwäbisch Hall; TUM Klinikum rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, 2University Medical Center Göttingen, 3argenx, 4University of Minnesota, 5Amsterdam UMC, University of Amsterdam, 6University of North Carolina, Chapel Hill, 7University of Pennsylvania
Objective:

ADHERE REAL will assess the real-world effectiveness of subcutaneous efgartigimod PH20 in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and describe their treatment journey and healthcare resource utilization.

Background:

CIDP, an immune-mediated neuropathy, causes progressive muscle weakness and sensory disturbance. Efgartigimod, a human immunoglobulin (Ig)G1 antibody Fc fragment, reduces IgG recycling by blocking FcRn, reducing impact on CIDP pathophysiology. The efficacy and safety of subcutaneous efgartigimod PH20 in patients with CIDP was demonstrated in the registrational ADHERE trial.

Design/Methods:
This real-world, prospective, multicenter study will assess adults with CIDP across the US and Germany. Patients will be efgartigimod PH20-naïve at screening and initiate treatment in routine clinical practice. Clinician-assessed and patient-reported outcomes will be recorded regularly, and treatment/dosage changes or relapses will be recorded.
Results:

Change over time in scores, including adjusted Inflammatory Neuropathy Cause and Treatment and Inflammatory Rasch-built Overall Disability Score, will assess real-world effectiveness of efgartigimod PH20 and will be monitored via patient questionnaires, nurse assessments, and medical record review. Proportions of participants with CIDP relapse and with evidence of clinical improvement will be assessed. Assessment of patient-treatment journeys will include disease course, comorbidities, CIDP treatment, modifications, and timing/rationale for these changes. Healthcare resource utilization will be assessed by frequency, duration, and reasons for healthcare provider follow-ups, emergency room visits, and hospitalizations. As of April 2026, 43 participants have been enrolled in Germany; enrollment has begun in the US.

Conclusions:

This study will expand on the ADHERE trial and provide insights into the real-world usage of efgartigimod in patients with CIDP.

Generative AI Usage
No, did not use generative AI in the drafting or editing in this abstract.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.